Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Chau T. Dang, MD, discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.

David Ilson, MD, PhD, discusses pre-operative chemotherapy alone versus chemotherapy plus radiation therapy in patients with esophageal and gastroesophageal-junction cancers, and how data points to the latter being the better choice.

Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

Keith T. Flaherty, MD, discusses choosing between immunotherapy and targeted therapy in the frontline setting for patients with BRAF-mutated melanoma.

Zsofia K. Stadler, MD, provides extensive insight on microsatellite instability in colorectal cancer, the biology of and screening for MSI tumors, and the potential impact immunotherapy could have on the treatment paradigm.

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Kimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

Jedd D. Wolchok, MD, discusses the implications of the expanded FDA approval of nivolumab, and the potential for the PD-1 inhibitor as both a single agent and as part of a combination regimen in advanced melanoma

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.

Yelena Y. Janjigian, MD, discusses possible causes of the negative LOGiC trial results, HER2 as a driver in esophagogastric cancer, and what the future holds for lapatinib.

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

Philip W. Kantoff, MD, who has made many contributions in prostate cancer research at the laboratory and leadership levels, was honored in the Genitourinary Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Cancer drugs in the United States have increased 5- to 10-fold since 2000, but several analyses indicate that this increase in cost does not match improvements in health and overall survival.

Jimmie C. Holland, MD, whose emphasis on patients’ psychosocial needs helped humanize cancer care, was honored in the Supportive Care category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.

Clifford Hudis, MD, discusses the evolving adjuvant therapy options in HER2-positive breast cancer.

Gregory Riely, MD Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.

Clifford A. Hudis, MD, FACP, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, takes a deeper look at neoadjuvant treatment for patients with HER2-positive breast cancer.

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

The American Cancer Society now recommends that women at an average risk of breast cancer should wait to undergo annual screening mammography until they reach the age of 45.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.